mirikizumab vs risankizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
mirikizumab · Omvoh
Marketed by Eli Lilly
NCT03524092 · Phase 3 · completed
Randomized (re-randomization of induction responders), double-blind, placebo-controlled, adequately powered (n=544 in the key comparison), hard composite clinical/endoscopic primary endpoint that was statistically significant in the favorable direction (p<0.001) — meeting the 'strong' definition's full test.
Next expected readout: May 2027 · NCT07186101 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders): Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5) (met)
Result source: NCT03524092
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03398148 · Phase 2/3 · completed
Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.
Next expected readout: August 2027 · NCT06880744 (registry estimate)
Reported efficacy
clinical remission + endoscopic improvement met (met)
Result source: INSPIRE/COMMAND
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | mirikizumab | risankizumab |
|---|---|---|
| Clinical remission (induction) | 24.2% vs 13.3%+10.9 vs placeboNCT035180863 other results
| 20.3% vs 6.2%+14.1 vs placeboNCT033981484 other results
|
| Clinical remission (maintenance) | 49.9% vs 25.1%+24.8 vs placeboNCT03524092 | —Trial running · NCT03398135 |
| Clinical response (induction) | 63.5% vs 42.2%+21.3 vs placeboNCT035180863 other results
| 64.3% vs 35.7%+28.6 vs placeboNCT033981489 other results
|
| Endoscopic improvement (induction) | 13.1% vs 6.3%+6.8 vs placeboNCT025896652 other results
| 36.5% vs 12.1%+24.4 vs placeboNCT03398148 |
| Corticosteroid-free remission (maintenance) | —Not posted · NCT05784246 | —Trial running · NCT03398135 |
Clinical remission (induction)
- mirikizumab
- 24.2% vs 13.3%+10.9 vs placeboNCT03518086
3 other results
- 11.5% vs 4.8% NCT02589665
- 22.6% vs 4.8% NCT02589665
- 15.9% vs 4.8% NCT02589665
- risankizumab
- 20.3% vs 6.2%+14.1 vs placeboNCT03398148
4 other results
- 12.4% vs 1.7% NCT03398148
- 9.8% vs 1.7% NCT03398148
- 10.3% vs 1.7% NCT03398148
- 11.5% vs 1.7% NCT03398148
Clinical remission (maintenance)
- mirikizumab
- 49.9% vs 25.1%+24.8 vs placeboNCT03524092
- risankizumab
- —Trial running · NCT03398135
Clinical response (induction)
- mirikizumab
- 63.5% vs 42.2%+21.3 vs placeboNCT03518086
3 other results
- 49.2% vs 20.6% NCT02589665
- 59.7% vs 20.6% NCT02589665
- 41.3% vs 20.6% NCT02589665
- risankizumab
- 64.3% vs 35.7%+28.6 vs placeboNCT03398148
9 other results
- 52.2% vs 30.5% NCT03398148
- 46.2% vs 20% NCT03398148
- 43.5% vs 25% NCT03398148
- 45.9% vs 20% NCT03398148
- 45.9% vs 25% NCT03398148
- 53.4% vs 20% NCT03398148
- 37.9% vs 25% NCT03398148
- 42.6% vs 20% NCT03398148
- 32.8% vs 25% NCT03398148
Endoscopic improvement (induction)
- mirikizumab
- 13.1% vs 6.3%+6.8 vs placeboNCT02589665
2 other results
- 30.6% vs 6.3% NCT02589665
- 23.8% vs 6.3% NCT02589665
- risankizumab
- 36.5% vs 12.1%+24.4 vs placeboNCT03398148
Corticosteroid-free remission (maintenance)
- mirikizumab
- —Not posted · NCT05784246
- risankizumab
- —Trial running · NCT03398135
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. mirikizumab: 5 of 5 rows · risankizumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | mirikizumab Rows use multiple source trials | risankizumab |
|---|---|---|
| Endoscopic Remission responder rate · % of participants Induction | 36.3% (n=868) vs 21.1% (n=294) placebo @ 12wk300 mg IV Q4Wa,b NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 3 other source trials3.2% (n=62) vs 1.6% (n=63) placebo @ 12wk200 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.2% (n=63) vs 1.6% (n=63) placebo @ 12wk50 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 1.6% (n=61) vs 1.6% (n=63) placebo @ 12wk600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence | 4.9% (n=61) vs 0% (n=60) placebo @ 12wk*1200 mg IVc,a,b NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted show 4 more doses10.6% (n=650) vs 3.4% (n=325) placebo @ 12wk1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.6% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted 6.5% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted 8.2% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted |
| Dropout rate | —300 mg IVd NCT03524092 · Phase 3 show 30 more results—300 mg IV NCT03524092 · Phase 3 —300 mg IV NCT03524092 · Phase 3 —300 mg IV NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 11.5%200 mg SC NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 —300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 4.1%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 7.2%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 9.9%300 mg NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0%300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV / 200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence 0%10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 50 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —200 mg SC Q12W NCT02589665 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 6.6%600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.2%200 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —50 mg Q4W NCT02589665 · Phase 2 · registry result, not featured evidence | 4.9%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 10.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.8%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Discontinued due to AEs | —300 mg IVd NCT03524092 · Phase 3 show 30 more results—300 mg IV NCT03524092 · Phase 3 —300 mg IV NCT03524092 · Phase 3 —300 mg IV NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 7.7%200 mg SC NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 —200 mg SC NCT03524092 · Phase 3 —300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1.6%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1.6%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 1.2%300 mg NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV / 200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 50 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —200 mg SC Q12W NCT02589665 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.3%600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.2%200 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence —50 mg Q4W NCT02589665 · Phase 2 · registry result, not featured evidence | 3.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 0%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 3.3%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Serious AEs | 5.2%300 mg IVd NCT03524092 · Phase 3 show 30 more results6.1%300 mg IV NCT03524092 · Phase 3 3.3%300 mg IV NCT03524092 · Phase 3 16.7%300 mg IV NCT03524092 · Phase 3 3.3%200 mg SC NCT03524092 · Phase 3 13.5%200 mg SC NCT03524092 · Phase 3 3.3%200 mg SC NCT03524092 · Phase 3 9.1%200 mg SC NCT03524092 · Phase 3 2.8%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 8%300 mg IV Q4W NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 2.9%300 mg NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0%300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence 9.1%300 mg IV NCT04004611 · Phase 2 · registry result, not featured evidence —300 mg IV / 200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —200 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence 0%10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence 40%10 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 100 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence —10 mg/kg IV / 50 mg SC NCT04004611 · Phase 2 · registry result, not featured evidence 0%5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence 0%5 mg/kg IV NCT04004611 · Phase 2 · registry result, not featured evidence 4.4%200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 4.3%200 mg SC Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 2.2%200 mg SC Q12W NCT02589665 · Phase 2 · registry result, not featured evidence 5.2%1000 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.1%600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 5%600 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 3.2%200 mg IV Q4W NCT02589665 · Phase 2 · registry result, not featured evidence 0%50 mg Q4W NCT02589665 · Phase 2 · registry result, not featured evidence | 6.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results2.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.5%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.9%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.4%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.5%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 5.6%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.6%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 7.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.7%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Most frequent reported AEs | 300 mg IVd arthralgia 3.3% (placebo 4.2%) nasopharyngitis 3.3% (placebo 5.7%) headache 1.7% (placebo 1%) NCT03524092 · Phase 3 show 24 more results300 mg IV upper respiratory tract infection 9.1% (placebo 2.6%) anaemia 6.1% (placebo 4.7%) covid-19 6.1% (placebo 2.1%) NCT03524092 · Phase 3 300 mg IV anaemia 5.6% (placebo 4.7%) headache 5.6% (placebo 1%) arthralgia 3.3% (placebo 4.2%) NCT03524092 · Phase 3 300 mg IV covid-19 8.3% (placebo 2.1%) electrolyte imbalance 8.3% (placebo 0%) haemorrhoids 8.3% (placebo 1.6%) NCT03524092 · Phase 3 200 mg SC nasopharyngitis 7.2% (placebo 5.7%) arthralgia 6.7% (placebo 4.2%) colitis ulcerative 6.7% (placebo 18.2%) NCT03524092 · Phase 3 200 mg SC upper respiratory tract infection 15.4% (placebo 2.6%) covid-19 11.5% (placebo 2.1%) abdominal pain 7.7% (placebo 2.1%) NCT03524092 · Phase 3 200 mg SC arthralgia 7% (placebo 4.2%) nasopharyngitis 5.2% (placebo 5.7%) headache 4.8% (placebo 1%) NCT03524092 · Phase 3 200 mg SC uterine leiomyoma 14.3% (placebo 0%) upper respiratory tract infection 12.1% (placebo 2.6%) anorectal polyp 6.1% (placebo 1%) NCT03524092 · Phase 3 300 mg IV Q4W anaemia 3.2% (placebo 5.6%) colitis ulcerative 0% (placebo 0%) upper respiratory tract infection 0% (placebo 0%) NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg IV Q4W upper respiratory tract infection 12% (placebo 0%) anaemia 6.4% (placebo 5.6%) colitis ulcerative 2.4% (placebo 0%) NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg any event 7% any event 6.4% any event 5.8% NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg IV rash 18.2% dysmenorrhoea 16.7% arthralgia 9.1% NCT04004611 · Phase 2 · registry result, not featured evidence 300 mg IV injection site pain 27.3% asymptomatic covid-19 18.2% covid-19 18.2% NCT04004611 · Phase 2 · registry result, not featured evidence 10 mg/kg IV anaemia 20% covid-19 20% pollakiuria 20% NCT04004611 · Phase 2 · registry result, not featured evidence 10 mg/kg IV covid-19 40% anaemia 20% dyspepsia 20% NCT04004611 · Phase 2 · registry result, not featured evidence 5 mg/kg IV headache 30% pyrexia 20% abdominal pain upper 10% NCT04004611 · Phase 2 · registry result, not featured evidence 5 mg/kg IV headache 30% covid-19 20% injection site pain 20% NCT04004611 · Phase 2 · registry result, not featured evidence 200 mg SC Q4W nasopharyngitis 20.6% (placebo 9.5%) colitis ulcerative 10.3% (placebo 9.5%) back pain 8.8% (placebo 0%) NCT02589665 · Phase 2 · registry result, not featured evidence 200 mg SC Q4W arthralgia 12.8% (placebo 0%) nasopharyngitis 12.8% (placebo 9.5%) headache 10.6% (placebo 4.8%) NCT02589665 · Phase 2 · registry result, not featured evidence 200 mg SC Q12W nasopharyngitis 17.4% (placebo 9.5%) colitis ulcerative 15.2% (placebo 9.5%) influenza 8.7% (placebo 0%) NCT02589665 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W nasopharyngitis 7.3% (placebo 9.5%) dry skin 1% (placebo 0%) abdominal discomfort 0% (placebo 0%) NCT02589665 · Phase 2 · registry result, not featured evidence 600 mg IV Q4W nasopharyngitis 15.6% (placebo 9.5%) influenza 9.4% (placebo 0%) dry skin 6.3% (placebo 0%) NCT02589665 · Phase 2 · registry result, not featured evidence 600 mg IV Q4W nasopharyngitis 8.3% (placebo 9.5%) headache 6.7% (placebo 4.8%) nausea 5% (placebo 6.3%) NCT02589665 · Phase 2 · registry result, not featured evidence 200 mg IV Q4W nasopharyngitis 4.8% (placebo 9.5%) anaemia 3.2% (placebo 4.8%) nausea 3.2% (placebo 6.3%) NCT02589665 · Phase 2 · registry result, not featured evidence 50 mg Q4W nasopharyngitis 7.9% (placebo 9.5%) anaemia 6.3% (placebo 4.8%) headache 4.8% (placebo 4.8%) NCT02589665 · Phase 2 · registry result, not featured evidence | 1200 mg IV colitis ulcerative 4.9% (placebo 8.5%) headache 4.9% (placebo 5.1%) nasopharyngitis 4.9% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 12 more results1200 mg IV covid-19 4.6% (placebo 0%) anaemia 3.2% (placebo 3.4%) headache 2.9% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.9% (placebo 0%) headache 2.9% (placebo 5.1%) anaemia 1.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.7% (placebo 0%) anaemia 2.9% (placebo 3.4%) colitis ulcerative 1.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC nasopharyngitis 8.5% (placebo 6.8%) headache 7% (placebo 5.1%) colitis ulcerative 4.2% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC anaemia 8.5% (placebo 3.4%) covid-19 8.5% (placebo 0%) headache 8.5% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC headache 2.8% (placebo 5.1%) anaemia 1.4% (placebo 3.4%) nasopharyngitis 1.4% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC covid-19 5.6% (placebo 0%) colitis ulcerative 4.2% (placebo 8.5%) anaemia 2.8% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 8.6% (placebo 6.8%) headache 6.9% (placebo 5.1%) anaemia 1.7% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 7% (placebo 6.8%) headache 6.5% (placebo 5.1%) anaemia 3.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 10.8% (placebo 6.8%) anaemia 2.7% (placebo 3.4%) colitis ulcerative 2.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV dry skin 5.6% (placebo 0%) headache 5.6% (placebo 5.1%) nasopharyngitis 5.6% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 600 mg IV nasopharyngitis 8.1% (placebo 6.8%) bronchitis 6.5% (placebo 0%) dry skin 3.2% (placebo 0%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
Notes
- aTrial phases differ: Phase 2/3 versus Phase 3.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation comparability has not been reviewed for 27 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
mirikizumab
show 2 more results
show 2 more results
show 3 more results
+ 26 further endpoints in the CSV export.
risankizumab
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
+ 4 further endpoints in the CSV export.
Crohn's Disease
Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline
mirikizumab · Omvoh
Marketed by Eli Lilly
NCT03926130 · Phase 3 · completed
Randomized, triple-masked, placebo-controlled, adequately powered (n=1158 overall, ~778 in the placebo/mirikizumab primary comparison), with hard endoscopic (SES-CD response) and clinical remission co-primary endpoints, both meeting statistical significance (p<0.000001) favoring mirikizumab over placebo.
Next expected readout: September 2027 · NCT06997965 (registry estimate)
Reported efficacy
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52); Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab) (met)
Result source: NCT03926130
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03104413 · Phase 3 · completed
Design meets the 'strong' test: randomized, double-blind, placebo-controlled, adequately powered (n~600), with a hard endoscopic co-primary endpoint (SES-CD response) plus CDAI clinical remission, and both primary endpoint comparisons were statistically significant in the favorable direction for both doses vs placebo.
Next expected readout: March 2027 · NCT06063967 (registry estimate)
Reported efficacy
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12); US Specific: Percentage of Participants With Endoscopic Response (Week 12); Global Outside of US: Percentage of Participants With Clinical Remission (Week 12); Global Outside of US: Percentage of Participants With Endoscopic Response (Week 12): US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1)) (met)
Result source: NCT03104413
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | mirikizumab | risankizumab |
|---|---|---|
| Clinical remission (induction) | 37.7% vs 25.1%+12.6 vs placeboNCT03926130 | 42% vs 19.8%+22.2 vs placeboNCT0310441326 other results
|
| Endoscopic response (induction) | 32.5% vs 12.6%+19.9 vs placeboNCT039261303 other results
| 28.8% vs 11.2%+17.6 vs placeboNCT0310441310 other results
|
| Clinical remission (maintenance) | 54.1% vs 19.6%+34.5 vs placeboNCT03926130 | —Trial running · NCT06063967 |
| Endoscopic response (maintenance) | 48.4% vs 9%+39.4 vs placeboNCT03926130 | —Trial running · NCT06063967 |
Clinical remission (induction)
- mirikizumab
- 37.7% vs 25.1%+12.6 vs placeboNCT03926130
- risankizumab
- 42% vs 19.8%+22.2 vs placeboNCT03104413
26 other results
- 28.8% vs 11.2% NCT03104413
- 45.2% vs 24.6% NCT03105128
- 43.5% vs 21.7% NCT03105128
- 40.3% vs 19.8% NCT03104413
- 34.2% vs 11.2% NCT03104413
- 41.6% vs 24.6% NCT03105128
- 41% vs 21.7% NCT03105128
- 34.6% vs 19.3% NCT03104413
- 42% vs 19.8% NCT03104413
- 43.5% vs 21.7% NCT03105128
- 45.2% vs 24.6% NCT03105128
- 20.9% vs 11.2% NCT03104413
- 17.3% vs 8% NCT03104413
- 18.4% vs 10.3% NCT03105128
- 21% vs 9.1% NCT03105128
- 39.8% vs 19.3% NCT03104413
- 40.3% vs 19.8% NCT03104413
- 41% vs 21.7% NCT03105128
- 41.6% vs 24.6% NCT03105128
- 19.4% vs 11.2% NCT03104413
- 18.3% vs 8% NCT03104413
- 18.9% vs 10.3% NCT03105128
- 21.2% vs 9.1% NCT03105128
- 36.6% vs 15.4% NCT02031276
- 28% vs 15.4% NCT02031276
- 19.5% vs 15.4% NCT02031276
Endoscopic response (induction)
- mirikizumab
- 32.5% vs 12.6%+19.9 vs placeboNCT03926130
3 other results
- 43.8% vs 10.9% NCT02891226
- 37.5% vs 10.9% NCT02891226
- 25.8% vs 10.9% NCT02891226
- risankizumab
- 28.8% vs 11.2%+17.6 vs placeboNCT03104413
10 other results
- 34.6% vs 19.3% NCT03104413
- 40.3% vs 12% NCT03105128
- 40.3% vs 12% NCT03105128
- 34.2% vs 11.2% NCT03104413
- 39.8% vs 19.3% NCT03104413
- 32.1% vs 12% NCT03105128
- 32.1% vs 12% NCT03105128
- 36.6% vs 12.8% NCT02031276
- 31.7% vs 12.8% NCT02031276
- 26.8% vs 12.8% NCT02031276
Clinical remission (maintenance)
- mirikizumab
- 54.1% vs 19.6%+34.5 vs placeboNCT03926130
- risankizumab
- —Trial running · NCT06063967
Endoscopic response (maintenance)
- mirikizumab
- 48.4% vs 9%+39.4 vs placeboNCT03926130
- risankizumab
- —Trial running · NCT06063967
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. mirikizumab: 6 of 6 rows · risankizumab: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | mirikizumab Rows use multiple source trials | risankizumab Rows use multiple source trials |
|---|---|---|
| Endoscopic Remission responder rate · % of participants Induction | 10.9% (n=579) vs 4% (n=199) placebo @ 12wka,b NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 show 1 more dose17.6% (n=579) vs 7% (n=199) placebo @ 12wk NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 | 19.4% (n=191) vs 4.3% (n=187) placebo @ 12wk600 mga,b NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 3 more doses19.4% (n=191) vs 4.3% (n=187) placebo @ 12wk600 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 20.4% (n=191) vs 4.3% (n=187) placebo @ 12wk1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 20.4% (n=191) vs 4.3% (n=187) placebo @ 12wk1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 |
| FACIT-Fatigue absolute change · score Induction | 9.62 vs 2.9 placebo score @ 12wk1000 mg IV Q4Wa,c,d,b NCT02891226 · Phase 2 · registry result, not featured evidence show 2 more doses9.09 vs 2.9 placebo score @ 12wk600 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 10.81 vs 2.9 placebo score @ 12wk200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence | 11.2 vs 6 placebo score @ 12wk600mga,c,d,b NCT03105128 · Phase 3 · Crohn's Disease · phase 3 show 1 more dose10.1 vs 6 placebo score @ 12wk1200mg NCT03105128 · Phase 3 · Crohn's Disease · phase 3 |
| Dropout rate | 11.1%Mirikizumabe NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 show 16 more results33.3%Mirikizumab (Adolescents) NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 6.3%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 12.5%600 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —600 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 6.5%200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence | 1.9%600 mgf NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results—360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 2.9%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence —200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.7%Mirikizumabe NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 show 16 more results0%Mirikizumab (Adolescents) NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 9.4%600 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —600 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 3.2%200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence —200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence | —600 mgf NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results—360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 —600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 —600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence —180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence —200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 10.3%Mirikizumabe NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 show 16 more results0%Mirikizumab (Adolescents) NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 0%300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 4.3%300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 11%300 mg SC Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 3.1%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 10%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 15.3%1000 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 9.4%600 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%600 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence 0%200 mg IV Q4W NCT02891226 · Phase 2 · registry result, not featured evidence | 4.9%600 mgf NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results4.8%360 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 4.9%180 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 4.4%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 7.1%1200 mg NCT03104413 · Phase 3 · Crohn's Disease · phase 3 7.2%600mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 4.4%360mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 4.5%180mg SC NCT03105128 · Phase 3 · Crohn's Disease · phase 3 3.8%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 5.3%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 6%1200mg IV NCT03105128 · Phase 3 · Crohn's Disease · phase 3 0%600 mg IV NCT02513459 · Phase 2 · registry result, not featured evidence 35.4%180 mg SC NCT02513459 · Phase 2 · registry result, not featured evidence 9.8%600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence 10.9%600 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence 11.3%180 mg SC NCT02031276 · Phase 2 · registry result, not featured evidence 24.4%200 mg IV NCT02031276 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | e covid-19 16.3% (placebo 10%) anaemia 6.8% (placebo 4.7%) arthralgia 6.5% (placebo 4.7%) NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 show 16 more resultsarthralgia 16.7% (placebo 4.7%) covid-19 16.7% (placebo 10%) crohn's disease 16.7% (placebo 10%) NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3 300 mg SC Q4W abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 1.6%) alanine aminotransferase increased 0% (placebo 0%) NCT02891226 · Phase 2 · registry result, not featured evidence 300 mg SC Q4W arthralgia 13% (placebo 4.7%) nasopharyngitis 13% (placebo 1.6%) headache 8.7% (placebo 3.1%) NCT02891226 · Phase 2 · registry result, not featured evidence 300 mg SC Q4W nasopharyngitis 18.4% (placebo 1.6%) injection site reaction 13.2% (placebo 0%) headache 11.8% (placebo 3.1%) NCT02891226 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W vitamin d deficiency 50% (placebo 0%) abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 1.6%) NCT02891226 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W crohn's disease 100% (placebo 9.4%) respiratory tract infection viral 100% (placebo 1.6%) abdominal distension 0% (placebo 0%) NCT02891226 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 1.6%) alanine aminotransferase increased 0% (placebo 0%) NCT02891226 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W headache 10.9% (placebo 3.1%) nasopharyngitis 6.3% (placebo 1.6%) arthralgia 4.7% (placebo 4.7%) NCT02891226 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W headache 13% (placebo 3.1%) epididymitis 9.1% (placebo 0%) abdominal pain 8.7% (placebo 1.6%) NCT02891226 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W headache 10% (placebo 3.1%) nasopharyngitis 10% (placebo 1.6%) anaemia 6.7% (placebo 1.6%) NCT02891226 · Phase 2 · registry result, not featured evidence 1000 mg IV Q4W anaemia 8.5% (placebo 1.6%) fatigue 6.8% (placebo 4.7%) headache 6.8% (placebo 3.1%) NCT02891226 · Phase 2 · registry result, not featured evidence 600 mg IV Q4W pyrexia 9.4% (placebo 1.6%) weight increased 9.4% (placebo 0%) abdominal distension 6.3% (placebo 0%) NCT02891226 · Phase 2 · registry result, not featured evidence 600 mg IV Q4W vulvovaginal mycotic infection 25% (placebo 2.8%) anal incontinence 11.1% (placebo 0%) anxiety 11.1% (placebo 1.6%) NCT02891226 · Phase 2 · registry result, not featured evidence 200 mg IV Q4W abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 1.6%) alanine aminotransferase increased 0% (placebo 0%) NCT02891226 · Phase 2 · registry result, not featured evidence 200 mg IV Q4W alanine aminotransferase increased 6.5% (placebo 0%) anaemia 6.5% (placebo 1.6%) aspartate aminotransferase increased 6.5% (placebo 0%) NCT02891226 · Phase 2 · registry result, not featured evidence 200 mg IV Q4W abdominal pain 11.1% (placebo 1.6%) anaemia 11.1% (placebo 1.6%) arthralgia 11.1% (placebo 4.7%) NCT02891226 · Phase 2 · registry result, not featured evidence | 600 mgf headache 5.3% (placebo 5.3%) arthralgia 3.9% (placebo 3.9%) nasopharyngitis 3.9% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 show 16 more results360 mg arthralgia 2.4% (placebo 3.9%) headache 2.4% (placebo 5.3%) nausea 2.4% (placebo 4.8%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 180 mg arthralgia 4.9% (placebo 3.9%) crohn's disease 2.4% (placebo 6.3%) headache 2.4% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 1200 mg headache 4.9% (placebo 5.3%) arthralgia 4.4% (placebo 3.9%) nasopharyngitis 3.9% (placebo 5.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 1200 mg headache 7.1% (placebo 5.3%) nausea 7.1% (placebo 4.8%) crohn's disease 4.8% (placebo 6.3%) NCT03104413 · Phase 3 · Crohn's Disease · phase 3 600mg IV headache 6.4% (placebo 4.3%) nasopharyngitis 5.9% (placebo 2.7%) nausea 4.3% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 360mg SC headache 4.4% (placebo 4.3%) anaemia 2.9% (placebo 2.7%) crohn's disease 1.5% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 180mg SC crohn's disease 3% (placebo 5.4%) headache 1.5% (placebo 4.3%) nasopharyngitis 1.5% (placebo 2.7%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV nasopharyngitis 5.9% (placebo 2.7%) headache 5.4% (placebo 4.3%) nausea 3.5% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV headache 6.6% (placebo 4.3%) anaemia 5.3% (placebo 2.7%) nausea 3.9% (placebo 5.4%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 1200mg IV headache 3% (placebo 4.3%) anaemia 1.5% (placebo 2.7%) nasopharyngitis 1.5% (placebo 2.7%) NCT03105128 · Phase 3 · Crohn's Disease · phase 3 600 mg IV abdominal pain upper 25% ear pain 25% haematochezia 25% NCT02513459 · Phase 2 · registry result, not featured evidence 180 mg SC nasopharyngitis 30.8% gastroenteritis 23.1% fatigue 20% NCT02513459 · Phase 2 · registry result, not featured evidence 600 mg IV arthralgia 19.5% (placebo 10.3%) headache 12.2% (placebo 12.8%) abdominal pain 9.8% (placebo 12.8%) NCT02031276 · Phase 2 · registry result, not featured evidence 600 mg IV abdominal pain 10.9% (placebo 12.8%) nasopharyngitis 7.9% (placebo 7.7%) arthralgia 6.9% (placebo 10.3%) NCT02031276 · Phase 2 · registry result, not featured evidence 180 mg SC nasopharyngitis 14.5% (placebo 7.7%) arthralgia 9.7% (placebo 10.3%) headache 9.7% (placebo 12.8%) NCT02031276 · Phase 2 · registry result, not featured evidence 200 mg IV nausea 22% (placebo 10.3%) abdominal pain 14.6% (placebo 12.8%) arthralgia 14.6% (placebo 10.3%) NCT02031276 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTreatment context has not been resolved for both arms.
- cTrial phases differ: Phase 3 versus Phase 2.
- dPopulation comparability has not been reviewed for both studies.
- ePopulation comparability has not been reviewed for 15 of these studies.
- fPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
mirikizumab
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
risankizumab
show 15 more results
show 3 more results
show 3 more results
show 3 more results
show 15 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 3 more results
show 3 more results
show 3 more results
+ 27 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mirikizumab's landscape · risankizumab's landscape